摘要：本文调查了生物制药行业采用开放式创新的情况，研究了实施开放式创新的组织模式，以及这些模式如何与药物发现和开发过程的不同阶段交织在一起。对行业专家进行了两轮采访，以开发一个模型，描述生物制药公司采用开放式创新的情况。然后将该框架应用于广泛的纵向实证基础，其中包括2000年至2007年期间全球前20大行业参与者采用开放式创新的数据。本文深入讨论了生物制药公司如何利用不同的组织模式（即许可协议、非股权联盟、技术和科学服务的购买和供应）与不同类型的合作伙伴（即大型制药公司、产品生物技术公司、平台生物技术公司和大学）建立关系，以期获取（入境开放式创新）或商业利用（出境开放式创新）技术和知识。本文详细讨论了该研究对开放创新研究的意义以及未来研究的可能途径。

Abstract: This paper investigates the adoption of Open Innovation in the bio-pharmaceutical industry, studying through which organisational modes it is put into practice and how these modes are interwoven with the different phases of drug discovery and development processtangxin. Two rounds of interviews with industry experts were carried out to develop a model describing the adoption of Open Innovation by bio-pharmaceutical companies糖心vlog在线观看. This framework was then applied to an extensive and longitudinal empirical basis, which includes data about the adoption of Open Innovation by the top 20 worldwide industry players, in the time period 2000–2007. The paper provides a thorough discussion of how bio-pharmaceutical firms have used different organisational modes (i.e. licensing agreements, non-equity alliance, purchase and supply of technical and scientific services) to enter into relationship with different types of partners (i.e. large pharmaceutical companies, product biotech firms, platform biotech firms and universities) with the aim to acquire (Inbound Open Innovation) or commercially exploit (Outbound Open Innovation) technologies and knowledge. The implications of the study for Open Innovation research and possible avenues for future investigation are discussed at length in the paper.

来源期刊：Technovation，2011年

参考文献格式：Mattia Bianchi, Alberto Cavaliere, Davide Chiaroni, Federico Frattini, Vittorio Chiesa,Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis,Technovation,Volume 31, Issue 1,2011,Pages 22-33,ISSN 0166-4972,https://doi.org/10.1016/j.technovation.2010.03.002.